Advertisement

Related Videos

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Blase Polite, MD, MPP, FASCO, on Transforming the Drug Cost Curve in the United States: Not How But If

Mark Sculpher, PhD: How Do We Assess the Value of Cancer Drug Optimization?

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Advertisement

Advertisement




Sep
14
Today In Oncology
Adjuvant Alectinib Maintains Quality of Life During 2 Years of Treatment in Resected ALK-Positive NSCLC
High-Risk Prostate Cancer GETUG-AFU 18 Suggests a Role for Dose-Escalated Radiotherapy With Long-Term ADT
Extended-Interval Dosing of Tarlatamab Found Safe Effective in SCLC
Favorable Safety Profile Found for Subcutaneous Tarlatamab in ES-SCLC
Genomic Profiles Compared in Early- and Average-Onset Metastatic Colorectal Cancer
View More 
Advertisement
© 2026 HSP News Service, L.L.C.
Conexiant Oncology Logo